Intrathecal Nalbuphine Versus Midazolam in Cesarean Section
Launched by ZAGAZIG UNIVERSITY · Apr 14, 2019
Trial Information
Current as of August 31, 2025
Completed
Keywords
ClinConnect Summary
Analgesia is the main point for each patient postoperatively. It is important to provide good analgesia with less hazardous (1). Cesarean section is a painful operation in need for adequate postoperative analgesia (1). Adequate pain management is important to facilitate the functional recovery and enable the patients for rapid rehabilitation of their normal activity (2).
Cesarean section was done under general anesthesia (GA) or regional anesthesia. The subarachnoid blockade is the preferred procedure (3). It avoids the depressant effect of GA on neonate and also the risk of aspiration, wi...
Gender
FEMALE
Eligibility criteria
- • Inclusion Criteria: -
- • Female gender .
- • Age : 18 - 40 years old .
- • Physical status : ASA II .
- • Elective cesarean section
- Exclusion Criteria:
- • - Patient refusal .
- • History of hypertension or cardiac diseases .
- • Psychiatric disorders .
- • Coagulopathy .
- • Allergy to study drugs .
- • Contraindication to spinal anesthesia .
- • Failure of spinal anesthesia .
About Zagazig University
Zagazig University, a prominent educational and research institution located in Egypt, plays a pivotal role in advancing medical knowledge and promoting health innovations through its clinical trials. With a commitment to excellence in research, the university leverages its diverse expertise and state-of-the-art facilities to conduct rigorous clinical studies that aim to improve patient care and outcomes. By fostering collaboration among multidisciplinary teams, Zagazig University contributes significantly to the global medical community, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagazig, Eygpt/Zagazig, Egypt
Zagazig, , Egypt
Patients applied
Trial Officials
Olfat A I Amin, MD
Principal Investigator
Zagazig University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials